Inadequate sampling, testing, investigation and documentation of Merck & Co. Inc.'s Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.
"Two lots of rofecoxib pure were released for distribution despite analytical findings that they were contaminated with polypropylene fibers in...




